Cladribine is linked to lower risk for disability progression in patients with relapsing-remitting multiple sclerosis vs ...

Mesenchymal stem cell therapy shows promise for treating MS, but more research is needed on long-term safety and efficacy, a review found.

Treatment with fenebrutinib in a 2-year open-label extension study led to significantly reduced disease-related inflammatory activity in those with relapsing MS, according to speaker at ECTRIMS ...

In a cohort of Black and Hispanic individuals with relapsing MS, baseline comorbidities had no significant effect on the ...

Tyruko, the first biosimilar of Tysabri, is now available in the U.S., providing a lower-cost treatment option for adults ...

OMAHA, Neb. (WOWT/Gray News) - A Nebraska woman has become the first patient in the world to undergo a groundbreaking new treatment for multiple sclerosis. Seven years ago, Jan Janisch-Hanzlik began ...